The clinical trials landscape in immunoglobulin light chain amyloidosis: a systematic review.
作者信息
Ramachandran Ramya, Shah Darshi, Luo Catherine, Shah Veer, Cliff Edward R Scheffer, Sanchorawala Vaishali, Lentzsch Suzanne, Chakraborty Rajshekhar
机构信息
Medical City Healthcare, Hospital Corporation of America, Arlington, TX.
Renaissance School of Medicine at Stony Brook University, Stony Brook, NY.
出版信息
Blood Adv. 2024 Jul 9;8(13):3464-3467. doi: 10.1182/bloodadvances.2024012737.
Abstract
摘要
相似文献
1
The clinical trials landscape in immunoglobulin light chain amyloidosis: a systematic review.免疫球蛋白轻链淀粉样变性的临床试验概况：一项系统综述。
Blood Adv. 2024 Jul 9;8(13):3464-3467. doi: 10.1182/bloodadvances.2024012737.
2
How We Manage Systemic Immunoglobulin Heavy Chain Amyloidosis (AH Amyloidosis) and Immunoglobulin Heavy-and-Light-Chain Amyloidosis (AH/AL Amyloidosis).我们如何管理系统性免疫球蛋白重链淀粉样变性（AH淀粉样变性）和免疫球蛋白重链与轻链淀粉样变性（AH/AL淀粉样变性）。
Clin Lymphoma Myeloma Leuk. 2020 Nov;20(11):e826-e831. doi: 10.1016/j.clml.2020.06.017. Epub 2020 Jun 28.
3
Unfolding Cardiac Amyloidosis -From Pathophysiology to Cure.心脏淀粉样变性的发病机制与治疗进展
Curr Med Chem. 2019;26(16):2865-2878. doi: 10.2174/0929867325666180104153338.
4
COVID-19 and Light Chain Amyloidosis, Adding Insult to Injury.COVID-19 与轻链淀粉样变性，雪上加霜。
Am J Med. 2022 Apr;135 Suppl 1:S49-S52. doi: 10.1016/j.amjmed.2022.01.005. Epub 2022 Jan 23.
5
Recent advances in understanding and treating immunoglobulin light chain amyloidosis.免疫球蛋白轻链淀粉样变性病的认识与治疗新进展
F1000Res. 2018 Aug 29;7. doi: 10.12688/f1000research.15353.1. eCollection 2018.
6
Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis.替卡泊单抗治疗系统性免疫球蛋白轻链淀粉样变性的安全性和有效性。
Blood Cancer J. 2023 Nov 27;13(1):172. doi: 10.1038/s41408-023-00950-3.
7
Treatment of immunoglobulin light chain (primary or AL) amyloidosis.免疫球蛋白轻链（原发性或 AL）淀粉样变性的治疗。
Oncology (Williston Park). 2011 Jun;25(7):620-6.
8
In search of the most effective therapy for light chain amyloidosis.寻找治疗轻链淀粉样变性的最有效疗法。
Amyloid. 2022 Mar;29(1):67-68. doi: 10.1080/13506129.2021.1974832. Epub 2021 Sep 12.
9
First report of safety and efficacy of daratumumab in 2 cases of advanced immunoglobulin light chain amyloidosis.达雷妥尤单抗治疗2例晚期免疫球蛋白轻链淀粉样变性的安全性和有效性的首例报告。
Blood. 2016 Oct 13;128(15):1987-1989. doi: 10.1182/blood-2016-06-722496. Epub 2016 Aug 19.
10
Relapsed systemic light chain amyloidosis - in search of a higher bar.复发性系统性轻链淀粉样变性——寻求更高标准。
Bone Marrow Transplant. 2024 Apr;59(4):441-443. doi: 10.1038/s41409-024-02203-8. Epub 2024 Jan 23.
引用本文的文献
1
Defying the odds: 30 years in AL amyloidosis research-recent barriers to clinical trial enrollment.逆势而行：30年AL型淀粉样变性研究——近期临床试验入组的障碍
Blood Adv. 2024 Nov 26;8(22):5826-5828. doi: 10.1182/bloodadvances.2024014262.
本文引用的文献
1
Complete responses in AL amyloidosis are unequal: the impact of free light chain mass spectrometry in AL amyloidosis.轻链型淀粉样变性的完全缓解并不相同：游离轻链质谱分析在轻链型淀粉样变性中的影响
Blood. 2024 Mar 28;143(13):1259-1268. doi: 10.1182/blood.2023022399.
2
Reduced early mortality with Daratumumab-based frontline therapy in AL amyloidosis: A retrospective cohort study.达雷妥尤单抗一线治疗降低 AL 型淀粉样变性早期死亡率：一项回顾性队列研究
Am J Hematol. 2024 Mar;99(3):477-479. doi: 10.1002/ajh.27179. Epub 2023 Dec 15.
3
Predictors of treatment response and survival outcomes in patients with advanced cardiac AL amyloidosis.晚期心脏淀粉样变性患者的治疗反应和生存结局的预测因素。
Blood Adv. 2023 Oct 24;7(20):6080-6091. doi: 10.1182/bloodadvances.2023010324.
4
Health-Related Quality of Life Instruments for Clinical Trials in AL Amyloidosis: Report from the Amyloidosis Forum HRQOL Working Group.用于 AL 型淀粉样变性临床试验的健康相关生活质量评估工具：淀粉样变性论坛 HRQOL 工作组报告
Patient Relat Outcome Meas. 2023 May 18;14:153-169. doi: 10.2147/PROM.S399658. eCollection 2023.
5
First report of outcomes in patients with stage IIIb AL amyloidosis treated with Dara-VCD front-line therapy.Dara-VCD 一线疗法治疗 IIIb 期淀粉样变性病患者的结果首次报告。
Br J Haematol. 2023 Jun;201(5):913-916. doi: 10.1111/bjh.18733. Epub 2023 Mar 10.
6
Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study.硼替佐米、环磷酰胺和地塞米松联合或不联合达雷妥尤单抗治疗轻链淀粉样变性患者的健康相关生活质量：ANDROMEDA 研究结果。
Am J Hematol. 2022 Jun 1;97(6):719-730. doi: 10.1002/ajh.26536. Epub 2022 Mar 30.
7
How I treat AL amyloidosis.我如何治疗AL型淀粉样变性。
Blood. 2022 May 12;139(19):2918-2930. doi: 10.1182/blood.2020008737.
8
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.达雷妥尤单抗治疗免疫球蛋白轻链淀粉样变性。
N Engl J Med. 2021 Jul 1;385(1):46-58. doi: 10.1056/NEJMoa2028631.
9
Changes in patient-reported outcomes in light chain amyloidosis in the first year after diagnosis and relationship to NT-proBNP change.在诊断后第一年轻链淀粉样变性患者报告结局的变化及其与 NT-proBNP 变化的关系。
Blood Cancer J. 2021 Feb 1;11(2):29. doi: 10.1038/s41408-021-00412-8.
10
Comparing measures of hematologic response after high-dose melphalan and stem cell transplantation in AL amyloidosis.比较高剂量马法兰和干细胞移植治疗 AL 淀粉样变性后的血液学反应的测量值。
Blood Cancer J. 2020 Sep 1;10(8):88. doi: 10.1038/s41408-020-00354-7.
Zotero 插件